Clinical application of boron neutron capture therapy for cancer treatment: A systematic review

Abstract

Boron neutron capture therapy (BNCT) combines boron drug delivery and heavy-ion therapy. The key factors in the application of BNCT are high-quality neutron beams and boron-containing compounds. It can be used to treat gliomas, meningiomas, melanomas, and recurrent head and neck cancers. To promote the research and development of accelerator-based neutron sources, increase the tumor targeting capability of boron drugs, and improve BNCT efficacy in treating malignancies, this review provides an overview of the development of boron-containing compounds and the progress made in clinical studies using BNCT.

Keywords

boron neutron capture therapy / cancer treatment / heavy-ion therapy

References

[1] Coderre JA, Morris GM. The radiation biology of boron neutron capture therapy. Radiat Res. 1999; 151(1): 1–18.

[2] He H, Li J, Jiang P, et al. The basis and advances in clinical application of boron neutron capture therapy. Radiat Oncol. 2021; 16(1): 216.

[3] Kinashi Y, Takahashi S, Kashino G, et al. DNA double-strand break induction in Ku80-deficient CHO cells following boron neutron capture reaction. Radiat Oncol. 2011; 6: 106.

[4] Sato A, Itoh T, Imamichi S, et al. Proteomic analysis of cellular response induced by boron neutron capture reaction in human squamous cell carcinoma SAS cells. Appl Radiat Isot. 2015;106: 213–219.

[5] Wang P, Zhen H, Jiang X, et al. Boron neutron capture therapy induces apoptosis of glioma cells through Bcl-2/Bax. BMC Cancer. 2010; 10: 661.

[6] Faião-Flores F, Coelho PR, Arruda-Neto JD, Maria-Engler SS, Maria DA. Cell cycle arrest, extracellular matrix changes and intrinsic apoptosis in human melanoma cells are induced by Boron Neutron Capture Therapy. Toxicol In Vitro. 2013; 27(4): 1196–1204.

[7] Fujita Y, Kato I, Iwai S, et al. Role of p53 mutation in the effect of boron neutron capture therapy on oral squamous cell carcinoma. Radiat Oncol. 2009; 4: 63.

[8] Huang CY, Lai ZY, Hsu TJ, Chou FI, Liu HM, Chuang YJ. Boron Neutron Capture Therapy Eliminates Radioresistant Liver Cancer Cells by Targeting DNA Damage and Repair Responses. J Hepatocell Carcinoma. 2022; 9: 1385–1401.

[9] Trivillin VA, Langle YV, Palmieri MA, et al. Evaluation of local, regional and abscopal effects of Boron Neutron Capture Therapy (BNCT) combined with immunotherapy in an ectopic colon cancer model. Br J Radiol. 2021; 94(1128): 20210593.

[10] Yoneyama T, Hatakeyama S, Sutoh Yoneyama M, et al. Tumor vasculature-targeted 10B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy. BMC Cancer. 2021; 21(1): 72.

[11] Khan AA, Maitz C, Quanyu C, Hawthorne F. BNCT induced immunomodulatory effects contribute to mammary tumor inhibition. PLoS One. 2019; 14(9): e0222022.

[12] Barth RF, Soloway AH, Fairchild RG, Brugger RM. Boron neutron capture therapy for cancer. Realities and prospects. Cancer. 1992; 70(12): 2995–3007.

[13] Soloway AH, Hatanaka H, Davis MA. Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compounds. J Med Chem. 1967; 10(4): 714–717.

[14] Fukuda H. Response of Normal Tissues to Boron Neutron Capture Therapy (BNCT) with (10)B-Borocaptate Sodium (BSH) and (10)B-Paraboronophenylalanine (BPA). Cells. 2021; 10(11): 2883.

[15] Kankaanranta L, Seppälä T, Koivunoro H, et al. L-boronophenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: a Phase I study. Int J Radiat Oncol Biol Phys. 2011; 80(2): 369–376.

[16] Kankaanranta L, Seppälä T, Koivunoro H, et al. Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial. Int J Radiat Oncol Biol Phys. 2012; 82(1): e67-75.

[17] Capuani S, Gili T, Bozzali M, et al. L-DOPA preloading increases the uptake of borophenylalanine in C6 glioma rat model: a new strategy to improve BNCT efficacy. Int J Radiat Oncol Biol Phys. 2008; 72(2): 562–567.

[18] Sköld K, H-Stenstam B, Diaz AZ, Giusti V, Pellettieri L, Hopewell JW. Boron Neutron Capture Therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA-f. Acta Neurol Scand. 2010; 122(1): 58–62.

[19] Suzuki M, Sakurai Y, Nagata K, et al. Impact of intra-arterial administration of boron compounds on dose-volume histograms in boron neutron capture therapy for recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys. 2006; 66(5): 1523–1527.

[20] Kusaka S, Morizane Y, Tokumaru Y, et al. Boron Delivery to Brain Cells via Cerebrospinal Fluid (CSF) Circulation for BNCT in a Rat Melanoma Model. Biology (Basel). 2022; 11(3): 397.

[21] Lin YC, Lee YJ, Chen YW, Wang SY, Chou FI. Evaluation of the Key Advantages between Two Modalities of Boronophenylalanine Administration for Clinical Boron Neutron Capture Therapy Using an Animal Model. Cells. 2022; 11(17): 2736.

[22] Wyzlic IM, Tjarks W, Soloway AH, Anisuzzaman AK, Rong FG, Barth RF. Strategies for the design and synthesis of boronated nucleic acid and protein components as potential delivery agents for neutron capture therapy. Int J Radiat Oncol Biol Phys. 1994; 28(5): 1203–1213.

[23] Li J, Shi Y, Zhang Z, et al. A Metabolically Stable Boron-Derived Tyrosine Serves as a Theranostic Agent for Positron Emission Tomography Guided Boron Neutron Capture Therapy. Bioconjug Chem. 2019; 30(11): 2870–2878.

[24] Sumitani S, Oishi M, Yaguchi T, et al. Pharmacokinetics of core-polymerized, boron-conjugated micelles designed for boron neutron capture therapy for cancer. Biomaterials. 2012; 33(13): 3568–3577.

[25] Shi Y, Li J, Zhang Z, et al. Tracing Boron with Fluorescence and Positron Emission Tomography Imaging of Boronated Porphyrin Nanocomplex for Imaging-Guided Boron Neutron Capture Therapy. ACS Appl Mater Interfaces. 2018; 10(50): 43387–43395.

[26] Kawabata S, Yang W, Barth RF, et al. Convection enhanced delivery of carboranylporphyrins for neutron capture therapy of brain tumors. J Neurooncol. 2011; 103(2): 175–185.

[27] Li J, Sun Q, Lu C, et al. Boron encapsulated in a liposome can be used for combinational neutron capture therapy. Nat Commun. 2022; 13(1): 2143.

[28] Fujimoto T, Teraishi F, Kanehira N, et al. BNCT pancreatic cancer treatment strategy with glucose-conjugated boron drug. Biomaterials. 2024; 309: 122605.

[29] Fujimura A, Yasui S, Igawa K, et al. In Vitro Studies to Define the Cell-Surface and Intracellular Targets of Polyarginine-Conjugated Sodium Borocaptate as a Potential Delivery Agent for Boron Neutron Capture Therapy. Cells. 2020; 9(10): 2149.

[30] Zavjalov E, Zaboronok A, Kanygin V, et al. Accelerator-based boron neutron capture therapy for malignant glioma: a pilot neutron irradiation study using boron phenylalanine, sodium borocaptate and liposomal borocaptate with a heterotopic U87 glioblastoma model in SCID mice. Int J Radiat Biol. 2020; 96(7): 868–878.

[31] Iguchi Y, Michiue H, Kitamatsu M, et al. Tumor-specific delivery of BSH-3R for boron neutron capture therapy and positron emission tomography imaging in a mouse brain tumor model. Biomaterials. 2015; 56: 10–17.

[32] Maruyama K, Ishida O, Kasaoka S, et al. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT). J Control Release. 2004; 98(2): 195–207.

[33] Zaboronok A, Khaptakhanova P, Uspenskii S, et al. Polymer-Stabilized Elemental Boron Nanoparticles for Boron Neutron Capture Therapy: Initial Irradiation Experiments. Pharmaceutics. 2022; 14(4): 761.

[34] Tsurubuchi T, Shirakawa M, Kurosawa W, et al. Evaluation of a Novel Boron-Containing alpha-D-Mannopyranoside for BNCT. Cells. 2020; 9(5): 1277.

[35] Vorobyeva MA, Dymova MA, Novopashina DS, et al. Tumor Cell-Specific 2'-Fluoro RNA Aptamer Conjugated with Closo-Dodecaborate as A Potential Agent for Boron Neutron Capture Therapy. Int J Mol Sci. 2021; 22(14): 7326.

[36] Tsujino K, Kashiwagi H, Nishimura K, et al. Improved Boron Neutron Capture Therapy Using Integrin alphavbeta3-Targeted Long-Retention-Type Boron Carrier in a F98 Rat Glioma Model. Biology (Basel). 2023; 12(3): 377.

[37] Fithroni AB, Kobayashi K, Uji H, et al. Novel Self-Forming Nanosized DDS Particles for BNCT: Utilizing A Hydrophobic Boron Cluster and Its Molecular Glue Effect. Cells. 2022; 11(20): 3307.

[38] Quan H, Fan L, Huang Y, et al. Hyaluronic acid-decorated carborane-TAT conjugation nanomicelles: A potential boron agent with enhanced selectivity of tumor cellular uptake. Colloids Surf B Biointerfaces. 2021; 204: 111826.

[39] Gruzdev DA, Telegina AA, Levit GL, et al. Carborane-Containing Folic Acid bis-Amides: Synthesis and In Vitro Evaluation of Novel Promising Agents for Boron Delivery to Tumour Cells. Int J Mol Sci. 2022; 23(22): 13726.

[40] Kuthala N, Vankayala R, Li YN, Chiang CS, Hwang KC. Engineering Novel Targeted Boron-10-Enriched Theranostic Nanomedicine to Combat against Murine Brain Tumors via MR Imaging-Guided Boron Neutron Capture Therapy. Adv Mater. 2017; 29(31):101002.

[41] Alberti D, Piña Marcos JN, Rakhshan S, et al. Cobaltabis(dicarbollide) [ o-COSAN]- loaded apoferritin: an innovative high-capacity boron delivery system to target tumour cells for BNCT applications. Nanoscale. 2025;17(18): 11624–11633.

[42] Alkins RD, Brodersen PM, Sodhi RN, Hynynen K. Enhancing drug delivery for boron neutron capture therapy of brain tumors with focused ultrasound. Neuro Oncol. 2013; 15(9): 1225–1235.

[43] Fan CH, Wang TW, Hsieh YK, et al. Enhancing Boron Uptake in Brain Glioma by a Boron-Polymer/Microbubble Complex with Focused Ultrasound. ACS Appl Mater Interfaces. 2019; 11(12): 11144–11156.

[44] Tani H, Kurihara H, Hiroi K, et al. Correlation of (18)F-BPA and (18)F-FDG uptake in head and neck cancers. Radiother Oncol. 2014; 113(2): 193–197.

[45] Chen J, Xu M, Li Z, et al. A Bis-Boron Amino Acid for Positron Emission Tomography and Boron Neutron Capture Therapy. Angew Chem Int Ed Engl. 2025; 64(1): e202413249.

[46] Miyatake S, Kawabata S, Yokoyama K, et al. Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. J Neurooncol. 2009; 91(2): 199–206.

[47] Henriksson R, Capala J, Michanek A, et al. Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol. 2008; 88(2): 183–191.

[48] Kawabata S, Miyatake S, Nonoguchi N, et al. Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients. Appl Radiat Isot. 2009; 67(7-8 Suppl): S15-18.

[49] Chadha M, Capala J, Coderre JA, et al. Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory. Int J Radiat Oncol Biol Phys. 1998; 40(4): 829–834.

[50] Kawabata S, Suzuki M, Hirose K, et al. Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study. Neurooncol Adv. 2021; 3(1): vdab067.

[51] Takai S, Wanibuchi M, Kawabata S, et al. Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up. Neuro Oncol. 2022; 24(1): 90–98.

[52] Miyatake S, Tamura Y, Kawabata S, Iida K, Kuroiwa T, Ono K. Boron neutron capture therapy for malignant tumors related to meningiomas. Neurosurgery. 2007; 61(1): 82–90.

[53] Kawabata S, Hiramatsu R, Kuroiwa T, Ono K, Miyatake S. Boron neutron capture therapy for recurrent high-grade meningiomas. J Neurosurg. 2013; 119(4): 837–844.

[54] Takeuchi K, Kawabata S, Hiramatsu R, et al. Boron Neutron Capture Therapy for High-Grade Skull-Base Meningioma. J Neurol Surg B Skull Base. 2018; 79(Suppl 4): S322-327.

[55] Fukuda H, Hiratsuka J, Kobayashi T, et al. Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor. Australas Phys Eng Sci Med. 2003; 26(3): 97–103.

[56] Hiratsuka J, Kamitani N, Tanaka R, et al. Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT). J Radiat Res. 2020; 61(6): 945–951.

[57] Menéndez PR, Roth BM, Pereira MD, et al. BNCT for skin melanoma in extremities: updated Argentine clinical results. Appl Radiat Isot. 2009; 67(7-8 Suppl): S50-53.

[58] Koivunoro H, Kankaanranta L, Seppälä T, Haapaniemi A, Mäkitie A, Joensuu H. Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma: An analysis of dose response and survival. Radiother Oncol. 2019; 137: 153–158.

[59] Hirose K, Konno A, Hiratsuka J, et al. Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan ((10)B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial. Radiother Oncol. 2021; 155: 182–187.

[60] Haapaniemi A, Kankaanranta L, Saat R, et al. Boron Neutron Capture Therapy in the Treatment of Recurrent Laryngeal Cancer. Int J Radiat Oncol Biol Phys. 2016; 95(1): 404–410.

[61] Wang LW, Chen YW, Ho CY, et al. Fractionated Boron Neutron Capture Therapy in Locally Recurrent Head and Neck Cancer: A Prospective Phase I/II Trial. Int J Radiat Oncol Biol Phys. 2016; 95(1): 396–403.

[62] Suzuki M, Tanaka H, Sakurai Y, et al. Impact of accelerator-based boron neutron capture therapy (AB-BNCT) on the treatment of multiple liver tumors and malignant pleural mesothelioma. Radiother Oncol. 2009; 92(1): 89–95.

[63] Suzuki M, Sakurai Y, Hagiwara S, et al. First attempt of boron neutron capture therapy (BNCT) for hepatocellular carcinoma. Jpn J Clin Oncol. 2007; 37(5): 376–381.

[64] Stylli, SS. Novel Treatment Strategies for Glioblastoma. Cancers (Basel). 2020; 12(10): 2883.

[65] Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004; 64(19): 7011–7021.

[66] Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987–996.

[67] Kondo N, Hikida M, Nakada M, et al. Glioma Stem-Like Cells Can Be Targeted in Boron Neutron Capture Therapy with Boronophenylalanine. Cancers (Basel). 2020; 12(10): 3040.

[68] Xiang J, Ma L, Gu Z, et al. A Boronated Derivative of Temozolomide Showing Enhanced Efficacy in Boron Neutron Capture Therapy of Glioblastoma. Cells. 2022; 11(7): 1173.

[69] Coderre J, Rubin P, Freedman A, et al. Selective ablation of rat brain tumors by boron neutron capture therapy. Int J Radiat Oncol Biol Phys. 1994; 28(5): 1067–1077.

[70] Nakagawa N, Akai F, Fukawa N, et al. Early effects of boron neutron capture therapy on rat glioma models. Brain Tumor Pathol. 2007; 24(1): 7–13.

[71] Nagane M, Nishikawa R, Narita Y, et al. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol. 2012; 42(10): 887–895.

[72] Miyatake S, Kawabata S, Hiramatsu R, Furuse M, Kuroiwa T, Suzuki M. Boron neutron capture therapy with bevacizumab may prolong the survival of recurrent malignant glioma patients: four cases. Radiat Oncol. 2014; 9: 6.

[73] Sköld K, Gorlia T, Pellettieri L, Giusti V, H-Stenstam B, Hopewell JW. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. Br J Radiol. 2010; 83(991): 596–603.

[74] Kawabata S, Miyatake S, Kuroiwa T, et al. Boron neutron capture therapy for newly diagnosed glioblastoma. J Radiat Res. 2009; 50(1): 51–60.

[75] Barth RF, Grecula JC, Yang W, et al.Combination of boron neutron capture therapy and external beam radiotherapy for brain tumors. Int J Radiat Oncol Biol Phys. 2004; 58(1): 267–277.

[76] Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004; 15(8): 1179–1186.

[77] Hirose K, Sato M. Clinical Results and Prognostic Factors in Boron Neutron Capture Therapy for Recurrent Squamous Cell Carcinoma of the Head and Neck Under the Japan National Health Insurance System: A Retrospective Study of the Initial 47 Patients. Int J Radiat Oncol Biol Phys. 2024; 120(3): 796–804.

[78] Aihara T, Morita N, Kamitani N, et al. Boron neutron capture therapy for advanced salivary gland carcinoma in head and neck. Int J Clin Oncol. 2014; 19(3): 437–444.

[79] Haginomori S, Miyatake S, Inui T, et al. Planned fractionated boron neutron capture therapy using epithermal neutrons for a patient with recurrent squamous cell carcinoma in the temporal bone: a case report. Head Neck. 2009; 31(3): 412–418.

[80] Miyaguchi J, Shiga K, Katagiri K, et al. Efficacy of boron neutron capture therapy (BNCT) for patients with oral cancer. Oral Oncol. 2025; 163: 107228.

[81] Sato M, Hirose K. Efficacy and safety of boron neutron capture therapy for Hypopharyngeal/Laryngeal cancer patients with previous head and neck irradiation. Radiother Oncol. 2024; 198: 110382.

[82] Wang LW, Liu YH, Chou FI, Jiang SH. Clinical trials for treating recurrent head and neck cancer with boron neutron capture therapy using the Tsing-Hua Open Pool Reactor. Cancer Commun (Lond). 2018; 38(1): 37.

[83] Tamura Y, Miyatake S, Nonoguchi N, et al. Boron neutron capture therapy for recurrent malignant meningioma. Case report. J Neurosurg. 2006; 105(6): 898–903.

[84] Miyatake S, Kawabata S, Nonoguchi N, et al. Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas. Neuro Oncol. 2009; 11(4): 430–436.

[85] Lan TL, Lin CF, Lee YY, et al. Advances in Boron Neutron Capture Therapy (BNCT) for Recurrent Intracranial Meningioma. Int J Mol Sci. 2023; 24(5): 4978.

[86] Nakahara Y, Ito H, Masuoka J, Abe T. Boron Neutron Capture Therapy and Photodynamic Therapy for High-Grade Meningiomas. Cancers (Basel). 2020; 12(5): 1334.

[87] Barth RF, Matalka KZ, Bailey MQ, et al. A nude rat model for neutron capture therapy of human intracerebral melanoma. Int J Radiat Oncol Biol Phys. 1994; 28(5): 1079–1088.

[88] Morita N, Hiratsuka J, Kondoh H, et al. Improvement of the tumor-suppressive effect of boron neutron capture therapy for amelanotic melanoma by intratumoral injection of the tyrosinase gene. Cancer Res. 2006; 66(7): 3747–3753.

[89] Suzuki M, Endo K, Satoh H, et al. A novel concept of treatment of diffuse or multiple pleural tumors by boron neutron capture therapy (BNCT). Radiother Oncol. 2008; 88(2): 192–195.

[90] Gadan MA, González SJ, Batalla M, Olivera MS, Policastro L, Sztejnberg ML. Reprint of Application of BNCT to the treatment of HER2+ breast cancer recurrences: Research and developments in Argentina. Appl Radiat Isot. 2015; 106: 260–264.

[91] Arima J, Taniguchi K, Yamamoto M, et al. Anti-tumor effect of boron neutron capture therapy in pelvic human colorectal cancer in a mouse model. Biomed Pharmacother. 2022; 154: 113632.

[92] Futamura G, Kawabata S, Siba H, et al. A case of radiation-induced osteosarcoma treated effectively by boron neutron capture therapy. Radiat Oncol. 2014; 9: 237.

[93] Yoshimura K, Kawabata S, Kashiwagi H, et al. Efficacy of Boron Neutron Capture Therapy in Primary Central Nervous System Lymphoma: In Vitro and In Vivo Evaluation. Cells. 2021; 10(12): 3398.

[94] Suzuki M, Sakurai Y, Masunaga S, et al. A preliminary experimental study of boron neutron capture therapy for malignant tumors spreading in thoracic cavity. Jpn J Clin Oncol. 2007; 37(4): 245–249.

[95] Deng S, Hu L, Chen G, et al. A PD-L1 siRNA-Loaded Boron Nanoparticle for Targeted Cancer Radiotherapy and Immunotherapy. Adv Mater. 2025; 37(13): e2419418.

[96] Seneviratne D, Advani P, Trifiletti DM, et al. Exploring the Biological and Physical Basis of Boron Neutron Capture Therapy (BNCT) as a Promising Treatment Frontier in Breast Cancer. Cancers (Basel). 2022; 14(12): 3009.

[97] Trivillin VA, Pozzi ECC, Colombo LL, et al. Abscopal effect of boron neutron capture therapy (BNCT): proof of principle in an experimental model of colon cancer. Radiat Environ Biophys. 2017; 56(4): 365–375.

[98] Kashihara T, Nakamura S, Yamazaki N, et al. Boron neutron capture therapy for cutaneous angiosarcoma and malignant melanoma: First in-human phase I clinical trial. Radiother Oncol. 2025; 202: 110607.

[99] Yong Z, Song Z, Zhou Y, et al. Boron neutron capture therapy for malignant melanoma: first clinical case report in China. Chin J Cancer Res. 2016; 28(6): 634–640.

[100] Mao H, Li J, Huang C, et al. Unveiling Cellular Responses and Underlying Immune Effects Induced by Boron Neutron Capture Therapy. Int J Radiat Oncol Biol Phys. 2025; S0360-3016(25)00417-1.

RIGHTS & PERMISSIONS

2025 The Author(s). Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.